Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our world-class scientists. This allows us to shorten the pre-clinical drug discovery stage by at least three-quarters and, in turn, substantially accelerate the delivery of new treatments to patients worldwide.
Exscientia recently announced a joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research. Exscientia will first apply its advanced biosensor platforms to rapidly screen the complete collection against key viral drug targets of SARS-CoV-2, the virus responsible for COVID-19.
Company Type: Enterprise
Region: US & Canada
Product: AI Phamatech
The Schrödinger Building Oxford Science Park